Project Grant HT94252410910
Award Date 9/30/24
Completion Date 9/29/27
Dollars Obligated $567K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Houston, TX 77030, USA
Similar Awards
- This $566,981 Project Grant was awarded on September 30, 2023 by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to The University of Texas MD Anderson Cancer Center. The funding supports a 3-year research project titled "TARGETING IMMUNE-CHECKPOINT PROTEIN B7-H3 IN ACUTE MYELOID LEUKEMIA" focused on evaluating novel treatments for acute myeloid leukemia. The University of Texas System is the parent organization for MD Anderson Cancer...
- The University of Texas MD Anderson Cancer Center received a $1,619,997 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to conduct research on targeting ferroptosis and mitochondrial pathways in acute myeloid leukemia. The 3-year award, which commenced on September 1, 2023, will support preclinical studies, clinical trials, and other research activities at the cancer center's facilities in Houston, Texas. As a component...
- Federal Grant Award Summary The University of Texas MD Anderson Cancer Center received a $735,751 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), effective September 1, 2025 through August 31, 2028. This award supports research combining TROP2 (Trophoblast cell surface antigen 2)-directed chimeric antigen receptor natural killer (CAR-NK) cells with HIF2A (hypoxia-inducible factor 2-alpha) inhibition to develop novel...
- The University of Texas MD Anderson Cancer Center was awarded a $1,306,991.00 Project Grant by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to conduct research on "ORGANOID-BASED MODELING AND THERAPEUTIC TARGETING OF TP53-MUTATED ACUTE MYELOID LEUKEMIA". The award has a performance period from August 1, 2025 to July 31, 2029 and will support advanced biomedical research aimed at transforming healthcare for military service members,...
- This Project Grant award from the Department of Defense's Military Medical Research and Development program (CFDA 12.420) provides $1,127,579.00 to The University of Texas MD Anderson Cancer Center, a component of the University of Texas System, to conduct a Phase 1b/2a clinical trial evaluating the anti-IL1RAP antibody nadunolimab in patients with myelodysplastic syndrome and acute myelogenous leukemia. The award commenced on September 30, 2023 and is scheduled for completion by September 29,...
- The Project Grant award of $542,663, funded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) and awarded to The University of Texas MD Anderson Cancer Center, supports research to develop novel targeted therapies for acute myeloid leukemia (AML) patients with MLL rearrangement (MLLR) or mutant NPM1 (mNPM1) - representing 40% of adult AML cases. The research aims to evaluate the efficacy of two novel small molecule inhibitors, FHD-286 and AU15330, which target the...
- Federal Project Grant Award Summary The University of Texas MD Anderson Cancer Center received a $1,144,500 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), effective September 1, 2025, through August 31, 2028. The award funds research targeting the PRMT3-IGF2BP1 axis-mediated epitranscriptomic reprogramming as a novel therapeutic strategy to overcome immunotherapy resistance in clear cell renal cell carcinoma...
- Federal Grant Award Summary The University of Texas MD Anderson Cancer Center received a $1,348,314 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) effective October 1, 2025, with completion targeted for September 30, 2028. The award supports research to develop T-cell immunotherapy products targeting neurofibromatosis type 1 (NF1)-associated malignant peripheral nerve sheath tumors (MPNST) through integrated antigen...
- Federal Project Grant Award Summary The University of Texas MD Anderson Cancer Center received a $489,767 Project Grant award from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), effective October 1, 2025, through September 30, 2028. The award funds research titled "Building T-Cell Products in NF1-Associated MPNST Through Antigen Discovery and Epigenome Targeting," which addresses the development of immunotherapeutic...
- Federal Project Grant Award Summary The University of Texas MD Anderson Cancer Center received a $893,525 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), effective September 1, 2025, through August 31, 2028. The award supports research targeting neuronal mimicry in SMARCB1-deficient renal medullary carcinoma treatment. This three-year initiative represents DHA's investment in advanced biomedical research aimed at...